Abstract: Methods for encasing bodies including smokeless tobacco or a tobacco substitute with a polymeric casing can include coating a compressed body with microfibers, applying tubular casings to compressed bodies, printing netting and webs on compressed bodies, injection molding around compressed bodies, applying a webbing to compressed bodies, placing compressed bodies into a skin forming bath, and including thermoplastic polymers in a compressed body.

Abstract: A formulation includes a base resin, a nucleating agent, and a blowing agent. The formulation can be used to form a container.

Abstract: Devices, methods and kits including a means for capturing red blood cells are provided. Such means include physical means for trapping red blood cells as well as agglutination agents, including hemagglutination agents, for retaining red blood cells in certain regions of the devices described herein. The physical means and agglutination agents provide separation of red blood cells from whole blood samples. Analysis of separated and/or agglutinated whole blood samples for the presence or absence of analytes of interest can be performed without interference from red blood cells. Devices, such as lateral flow assays with sample receiving zones comprising physical means and/or agglutination agents are also described. Certain agglutination agents include lectins and antibodies. such as red blood cell binding antibodies.

Abstract: Methods, devices and kits for rapid identification of individuals previously infected with, or vaccinated for, a bacterial or viral pathogen, such as SARS CoV-2 virus. Pathogen specific memory T cells, such as SARS CoV-2 specific memory T cells, provide indication of prior infection, if detected. Memory T cells are assayed by exposure to specific bacterial and/or viral antigens and then tested for activation by analysis of nucleotide content.

Abstract: A formulation includes a base resin, a nucleating agent, and a blowing agent. The formulation can be used to form a container.

Abstract: Embodiments of the present disclosure relate to chimeric antibodies which specifically bind to Borrelia decorin-binding protein A (DbpA) antigens and compositions or kits comprising such antibodies. The disclosure further relates to use of such antibodies in the detection of Borrelia sp. in samples, e.g., biological samples such as human blood and/or tissues of deer, ticks and other carriers of Borrelia. Embodiments of the disclosure further relate to diagnosis and/or therapy of Lyme disease using the chimeric antibodies and/or compositions containing the chimeric antibodies.

Abstract: Antibody fusions comprising any antibody or fragment thereof, operably linked, and expressed as a fusion with a label of interest are provided. Plasmids, vectors, host cells, methods, and kits related to the described antibody fusions are also provided. The antibody fusions are useful at least in the diagnostic and reagent setting.

Abstract: Embodiments of the present disclosure relate to chimeric antibodies which specifically bind to Borrelia decorin-binding protein A (DbpA) antigens and compositions or kits comprising such antibodies. The disclosure further relates to use of such antibodies in the detection of Borrelia sp. in samples, e.g., biological samples such as human blood and/or tissues of deer, ticks and other carriers of Borrelia. Embodiments of the disclosure further relate to diagnosis and/or therapy of Lyme disease using the chimeric antibodies and/or compositions containing the chimeric antibodies.